Joshua M. Staley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joshua M. Staley has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Andrew K. Godwin
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA
32 shared publications - Priyanka Sharma
University of Kansas Medical Center, Kansas City, KS
22 shared publications - Qamar J. Khan
University of Kansas Medical Center
21 shared publications - Shane R. Stecklein
University of Kansas Medical Center, Kansas City, KS
21 shared publications - Anne P. O'Dea
University of Kansas Medical Center, Westwood, Kansas
19 shared publications - Coralia Bueno
Medical Oncology Department, Hospital Universitario Infanta Cristina, Parla, Spain
19 shared publications
Latest Publications
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by adjuvant chemotherapy use among patients with residual disease
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Representativeness of study population
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by pathologic response
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by pathologic response
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Pathologic response categories
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Pathologic response categories
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
Survival by availability of sTILs data